Examining CD160 in Corneal Blood Vessels
CD160 Ans Corneal Graft: Expression in Corneal Vessels
CHU de Reims · NCT05009407
This study is testing how a specific protein in the eye might affect the success of corneal transplants for patients having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Locations | 1 site (Reims) |
| Trial ID | NCT05009407 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the expression of CD160 in corneal blood and lymphatic vessels to understand its role in corneal graft rejection. Patients undergoing corneal graft surgery at the Robert Debré University Hospital in Reims, France, will have their corneas analyzed through immunohistochemistry. The study aims to identify potential anti-angiogenic factors that could improve graft outcomes. Participants will undergo routine examinations and provide corneal samples during surgery for detailed analysis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for penetrating keratoplasty or deep anterior lamellar keratoplasty at the study site.
Not a fit: Patients not undergoing corneal graft surgery or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing corneal graft rejection.
How similar studies have performed: While the specific approach of examining CD160 in corneal vessels is novel, similar studies have shown promise in identifying anti-angiogenic factors in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
inclusion criteria : * 18-year-old or more patients * enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France * considered able to give an informed written consent exclusion criteria : * none
Where this trial is running
Reims
- Damien JOLLY — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Alexandre DENOYER
- Email: adenoyer@chu-reims.fr
- Phone: 03 26 78 78 88
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis, lymphangiogenesis